September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologies’ advanced artificial intelligence (AI) application, ClearRead CT, to further enhance its growing lung cancer screening program. ClearRead CT (computed tomography) employs a patented vessel suppression technology and was the first U.S. Food and Drug Administration (FDA)-cleared radiological device approved for all nodule types, including part-solid and ground glass.
According to Riverain, ClearRead CT is proven to improve both nodule detection accuracy and nodule search efficiency, has studies published in multiple peer review journals, and is in daily use at several leading healthcare institutions.
ClearRead CT was successfully integrated and demonstrated as part of an extensive trial at SimonMed. The SimonMed enterprise consists of a distributed, multi-center network with high exam volumes.
“SimonMed is extremely pleased to be working with Riverain Technologies, a pioneer in using AI for better detection and characterization of lung lesions allowing for more reliable diagnosis and treatment,” said John Simon, M.D., CEO of SimonMed. “SimonMed has always been on the forefront of technology and recognizes that AI is critical to the future of radiology as we continue to drive toward better patient outcomes.”
For more information: www.riveraintech.com
September 12, 2024 
